pharmacologic agent known to influence p21 expression, the synthetic triterpenoid and peroxisome proliferator-activated receptor gamma (PPARg) ligand, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) or its derivative di-CDDO, was shown to moderate virally-induced p21 expression and concurrently dampen HIV infection. CDDO is part of a class of synthetic triterpenoids based on natural products resembling steroids in their biogenesis and in their pleiotropic actions. A newly developed CDDO derivative, which is orally bioavailable, also suppresses HIV. These results, coupled with the evidence that macrophage p21 is a requisite macrophage facilitator of viral replication, intensify the interest to further develop these compounds as antiretroviral agents. The anti-retroviral effect of CDDO was evident when peripheral blood mononuclear cells (PBMC) were infected with a T-tropic (X4) or dual tropic viral (R5X4) strain of HIV–1. These studies suggest that these triterpenoids may aid in the control of retroviral replication. Neither p21 oligonucleotides nor CDDO were toxic to the cultured macrophages or peripheral blood mononuclear cells. Thus, p21 inhibitors could be safe and effective anti-HIV therapeutic candidates to be used independently and/or in conjunction with current anti-retroviral therapy. In this regard, CDDO will be entered into human trials for the first time in the near future for its anti-cancer indications, thereby determining its maximally tolerated dose for use in subsequent HIV/AIDS clinical trials. Current anti-retroviral therapy, often characterized by high toxicity and the emergence of drug resistant virus strains, may be augmented through the identification of these and other new anti-viral agents targeting host cellular molecules less prone to mutational events.

Inventors: Sharon M. Wahl, Nancy Vazquez-Maldonado, Teresa Greenwell-Wild (NIDCR).

Publications:

1. S.M. Wahl *et al.*, ''HIV accomplices and adversaries in macrophage infection,'' J. Leukoc. Biol. 2006, in press.

2. N. Vazquez *et al.*, ''Human immunodeficiency virus type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulation,'' J. Virol. (2005 Apr) 79(7):4479–4491.

Patent Status: U.S. Provisional Application No. 60/516,794 filed November 4, 2003 (HHS Reference No. E–114–2003/0–US–01); PCT Application No. PCT/US2004/36492 filed November 3, 2004, which published as WO 2005/046732 on May 26, 2005 (HHS Reference No. E–114–2003/0–PCT–02)

Licensing Status: Available for non-exclusive or exclusive licensing.

Licensing Contact: Sally Hu, PhD., M.B.A.; 301/435–5606; *hus@mail.nih.gov*

Collaborative Research Opportunity: The National Institute of Dental and Craniofacial Research, Oral Infection and Immunity Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact David W. Bradley, PhD., at *bradleyda@nidcr.nih.gov* or by phone at 301/402–0540 for more information.

Dated: May 18, 2006.

David R. Sadowski,

Acting Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. E6–8176 Filed 5–25–06; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center on Minority Health and Health Disparities; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Council on Minority Health and Health Disparities.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Council on Minority Health and Health Disparities.

Date: June 13, 2006.

Closed: 8:30 a.m. to 10 a.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Suite 800, Bethesda, MD 20892.

Open: 10 a.m. to 5 p.m.

Agenda: The agenda will include Opening Remarks, Administrative Matters, Director's Report, NCMHD, IC Strategic Plan Report, NIH Minority Research Training Programs Update, NCMHD Program Highlights, and other business of the Council.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Suite 800, Bethesda, MD 20892.

Contact Person: Donna Brooks, Asst. Director for Administration, National Center on Minority Health and Health Disparities, National Institutes of Health, 6707 Democracy Blvd., Suite 800, Bethesda, MD 20892. 301–435–2135. *brooksd@ncmhd.nih.gov.*

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Dated: May 18, 2006.

Anna Snouffer,

Acting Director, Office of the Federal Advisory Committee Policy.

[FR Doc. 06–4893 Filed 5–25–06; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Allergy, Immunology, and Transplantation Research Committee, Allergy, Immunology and Transplantation Research Committee (AITRC).

Date: June 12, 2006.

Time: 8 a.m. to 5 p.m.